NCT05205746: Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence |
|
|
| Completed | 2 | 158 | RoW | Recombinant NDV Vectored Vaccine for SARS-CoV-2, Placebo | Laboratorio Avi-Mex, S.A. de C.V., National Council of Science and Technology, Mexico, Instituto Nacional de Enfermedades Respiratorias | SARS CoV 2 Infection | 08/22 | 07/23 | | |